Presence of germline TP53 variants predisposed children to acute lymphoblastic leukemia and was associated with adverse outcomes compared with children who did not have these variants, according to the results of a new study.
Use of oral contraceptives may be beneficial for chemoprevention for a range of women with different baseline cancer risks, according to the results of a new study.
The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.
A diet rich in foods known to cause inflammation may increase the risk for colorectal cancer by about one-third, according to the results of a newly published study.
Treatment with hyperthermic intraperitoneal chemotherapy along with cytoreductive surgery resulted in better survival outcomes than surgery alone in patients with stage III epithelial ovarian cancer, according to a new study.
The FDA has expanded the approval of afatinib (Gilotrif) to include the first-line treatment of metastatic non–small-cell lung cancer patients whose tumors have non-resistant EGFR mutations, including three newly identified substitution mutations.
A 27-year-old immigrant from Africa presents with a hypopigmented arm lesion, and a biopsy is obtained. What is your diagnosis?
A 52-year-old woman develops a mass in her left breast, and a biopsy is performed. What is your diagnosis?
A test measuring circulating tumor cells in the bloodstream was able to accurately detect early-stage colorectal cancers, according to the results of a new study.
Adding abiraterone plus prednisone to ADT improves patient-reported outcomes and quality of life in patients with metastatic castration-naive prostate cancer.
Using gene expression profile tests like Oncotype DX to inform treatment decision-making for breast cancer is likely to be less cost-effective in community oncology practice than previous estimates had suggested.
Adjuvant everolimus did not improve disease-free survival in patients with DLBCL and confirmed complete response after 1 year of rituximab treatment.
Continuing letrozole therapy after 5 years of aromatase inhibitor therapy did not worsen quality-of-life measures in patients with HR-positive breast cancer.
A new analytical tool called topographic single-cell sequencing can reveal a direct genomic lineage between in situ and invasive tumor subpopulations, which may help decipher how and why some DCIS become invasive.
Bladder cancer patients with tumors smaller than 1 cm could be classified as “very-low-risk,” with recurrences that could arise after the 5-year surveillance period.